PMID: 8958181Jan 1, 1996Paper

Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team

Investigational New Drugs
D D Von Hoff

Abstract

2',2'-difluorodeoxycytidine (LY 188011, Gemcitabine, Gemzar) has recently been approved both in Europe for the treatment of patients with non-small cell lung cancer and in the United States for patients with pancreatic cancer. Since the initial discovery of the compound, we have been evaluating the in vitro activity of gemcitabine against human tumor colony-forming units taken directly from patients and growing in soft agar (in the human tumor cloning assay-HTCA). A total of 315 specimens have had gemcitabine tested against them with 44% giving evaluable results. Gemcitabine has been found to be active against colony-forming units from patients with non-small cell lung, breast, ovarian, and pancreatic cancers. A concentration-dependent in vitro response was noted with a higher in vitro response rate noted at 20 micrograms/ml than at 2.0 micrograms/ml. Based on subsequent clinical phase II data, the HTCA correctly predicted the wide spectrum of the clinical activity of gemcitabine.

References

Jun 15, 1978·The New England Journal of Medicine·S E SalmonT E Moon
Jul 29, 1977·Science·A W Hamburger, S E Salmon
Nov 11, 1992·Investigational New Drugs·D F MooreJ L Abbruzzese
Mar 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L AbbruzzeseM N Raber
Jan 17, 1990·Journal of the National Cancer Institute·D D Von HoffF M Muggia
Dec 1, 1985·Current Problems in Cancer·A R HanauskeD D Von Hoff
Jan 1, 1985·Cancer Investigation·A R Hanauske, D D Von Hoff
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S AamdalJ Verweij
Jan 1, 1994·Investigational New Drugs·C F PolleraF Calabresi
Jul 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CatimelJ Wanders
Oct 19, 1994·Journal of the National Cancer Institute·B LundJ P Neijt
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R P AbrattT A Rugg
May 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C SessaH Franklin
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H AndersonH H Hansen
Feb 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C F PolleraF Calabresi
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T J O'RourkeD D Von Hoff
Apr 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W C MertensD Wong

❮ Previous
Next ❯

Citations

Jun 23, 2011·Clinical Medicine Insights. Oncology·Hidetoshi HayashiKazuhiko Nakagawa
Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L SvancárováO S Nielsen
Oct 10, 2003·Cancer Investigation·D Richard IshmaelRobert E Nordquist
Jun 14, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Meaghan O'MalleyNithya Ramnath
Dec 13, 2006·Critical Reviews in Oncology/hematology·Lara Maria PasettoSilvio Monfardini
Mar 22, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C TibaldiUNKNOWN POLTO group
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaret TemperoJames Abbruzzese
Jan 26, 2005·British Journal of Cancer·J J ArendsM E T Tesselaar
Mar 18, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Christopher J CampenAmanda F Baker
Apr 18, 2017·Molecular and Clinical Oncology·Shufen ZhaoWensheng Qiu
Apr 18, 2001·The Oncologist·F J EstevaG N Hortobagyi
Jun 3, 2008·The Oncologist·Jacqueline NietoPeter Kozuch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.